Emergent Biosolutions (NYSE:EBS) SVP Paul Anthony Williams Sells 3,000 Shares of Company Stock

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Williams sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $6.53, for a total transaction of $19,590.00. Following the completion of the sale, the senior vice president owned 156,098 shares of the company’s stock, valued at approximately $1,019,319.94. This trade represents a 1.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of EBS stock opened at $7.24 on Tuesday. The business’s fifty day simple moving average is $6.11 and its 200-day simple moving average is $7.48. The company has a market cap of $371.25 million, a PE ratio of -2.04 and a beta of 2.28. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. Emergent Biosolutions Inc. has a 12-month low of $4.36 and a 12-month high of $14.06.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The firm had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. Analysts expect that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on EBS. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They issued an “underweight” rating for the company. Finally, Weiss Ratings raised shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Emergent Biosolutions presently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Trading of Emergent Biosolutions

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth about $39,525,000. Dimensional Fund Advisors LP increased its holdings in Emergent Biosolutions by 22.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after buying an additional 504,553 shares during the period. Ancora Advisors LLC purchased a new position in Emergent Biosolutions during the 2nd quarter worth approximately $8,949,000. Renaissance Technologies LLC raised its position in Emergent Biosolutions by 13.7% during the 1st quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock worth $5,445,000 after buying an additional 78,900 shares during the last quarter. Finally, Palisade Capital Management LP acquired a new stake in Emergent Biosolutions during the 2nd quarter valued at approximately $4,316,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.